PDF(Pubmed)
Abstract：
SARS-CoV-2 and blood-borne viral coinfections are well reported. Nevertheless, little is known regarding the seroprevalence of SARS-CoV-2 and coinfection with blood-borne viruses in hematologic malignancy patients in Ethiopia. We aimed to assess the seroprevalence of SARS-CoV-2 and associated infections with hepatitis B and other viruses among adolescent and adult acute leukemia patients at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. A cross-sectional study was conducted from July 2020 to June 2021. Blood samples were tested for the presence of anti-SARS-CoV-2, HBV, HCV, and HIV with ELISA kits and occult hepatitis B infection with a real-time polymerase chain reaction assay. Out of a total 110 cases, the SARS-CoV-2 seroprevalence was 35.5%. The prevalence showed a significant increment from July 2020 to the end of June 2021 (p = 0.015). In 22.7% and 2.7% of leukemia cases, HBV and HIV, respectively, were detected. No HCV was identified. The rate of SARS-CoV-2 coinfection with HBV and HIV was 28% (11/39) and 2.6% (1/39), respectively; however, there was no statistically significant association between SARS-CoV-2 seropositivity with HBV and HIV (p > 0.05). There is a need for viral screening in leukemia cases to monitor infections and inform management.
摘要：
SARS-CoV-2和血液传播的病毒共感染已得到充分报道。然而，关于埃塞俄比亚血液系统恶性肿瘤患者中SARS-CoV-2的血清阳性率和与血液传播病毒的合并感染知之甚少。我们旨在评估TikurAnbessa专科医院的青少年和成人急性白血病患者中SARS-CoV-2的血清阳性率以及与乙型肝炎和其他病毒相关的感染，亚的斯亚贝巴,埃塞俄比亚。一项横断面研究于2020年7月至2021年6月进行。检测血液样本是否存在抗SARS-CoV-2，HBV，HCV,和HIV的ELISA试剂盒和隐匿性乙型肝炎感染的实时聚合酶链反应测定。在总共110个案例中，SARS-CoV-2血清阳性率为35.5%。从2020年7月到2021年6月底，患病率显着增加（p=0.015）。在22.7%和2.7%的白血病病例中，HBV和HIV,分别,被检测到。未发现HCV。SARS-CoV-2合并感染HBV和HIV的比率分别为28%(11/39)和2.6%(1/39),分别；然而，SARS-CoV-2血清阳性与HBV和HIV之间无统计学意义（p>0.05）。需要在白血病病例中进行病毒筛查以监测感染并告知管理。
